Traders should monitor for the upcoming regulatory update in Q2 2026, which could significantly impact stock volatility depending on the FDA's feedback and path forward for tab-cel approval.
ATRA drugs
ATRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 12 $6.90entry
- T+1 · 8mo ago −5.80%α −5.20% · $6.50
- T+5 · 8mo ago −25.80%α −24.82% · $5.12
- T+20 · 7mo ago −32.61%α −34.58% · $4.65
- T+60 · 5mo ago +43.77%α +33.07% · $9.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter for the Biologics License Application of tabelecleucel (tab-cel), developed with partner Pierre Fabre Pharmaceuticals. The company expects to provide a regulatory update in the second quarter of 2026.
Key Facts
- Atara Biotherapeutics announced a scheduled Type A meeting with the FDA on March 12, 2026.
- The meeting will address the Complete Response Letter (CRL) for the Biologics License Application (BLA) of tabelecleucel (tab-cel).
- The BLA is held by partner Pierre Fabre Pharmaceuticals, with Atara's support.
- The purpose is to discuss resubmission with additional efficacy data collected since the original submission.
- A regulatory update is anticipated in the second quarter of 2026.
Financial Impact
No immediate financial impact disclosed; potential future revenue depends on successful BLA resubmission and approval.
Risk Factors
- FDA may require additional clinical data or trials, delaying approval.
- Resubmission may not result in approval, risking further regulatory setbacks.
- Atara's market cap remains low ($45M), indicating high sensitivity to binary regulatory outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-103127 |
| Document: 0001193125-26-103127-index-headers.html | 0001193125-26-103127 |
| Document: 0001193125-26-103127.txt | 0001193125-26-103127 |
Track record
11 reports on ATRA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
- Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
- Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
- Mar 12, 202635w ago 8-K Neutral 5/10 Viewing Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
- Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers